Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2008, Vol.111 (1)
Hauptverfasser: ESTEY, Elihu H, RAZA, Azra, GREENBERG, Peter L, CURTIN, Peter T, KLIMEK, Virginia M, SHAMMO, Jamile M, THOMAS, Deborah, KNIGHT, Robert D, SCHMIDT, Michele, WRIDE, Kenton, ZELDIS, Jerome B, LIST, Alan F, REEVES, James A, FELDMAN, Eric J, DEWALD, Gordon W, BENNETT, John M, JOACHIM DEEG, H, DREISBACH, Luke, SCHIFFER, Charles A, STONE, Richard M
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Hematologic and hematopoietic diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title Blood
container_volume 111
creator ESTEY, Elihu H
RAZA, Azra
GREENBERG, Peter L
CURTIN, Peter T
KLIMEK, Virginia M
SHAMMO, Jamile M
THOMAS, Deborah
KNIGHT, Robert D
SCHMIDT, Michele
WRIDE, Kenton
ZELDIS, Jerome B
LIST, Alan F
REEVES, James A
FELDMAN, Eric J
DEWALD, Gordon W
BENNETT, John M
JOACHIM DEEG, H
DREISBACH, Luke
SCHIFFER, Charles A
STONE, Richard M
description
format Article
fullrecord <record><control><sourceid>pascalfrancis</sourceid><recordid>TN_cdi_pascalfrancis_primary_19953465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19953465</sourcerecordid><originalsourceid>FETCH-pascalfrancis_primary_199534653</originalsourceid><addsrcrecordid>eNqNjstKBDEQRYMoOD7-oTbuJpJ-jfZ6UFy6cD8UnWo6Th5tqoYhP-R3GsQPcHW53APnXqhNM7TP2pjWXKqNMWan-_GpuVY3zJ_GNH3XDhv1_b4gE7TAcrIF0gyeInpnU3CWwEWQjJHnE7sUtaWVoqUoW_DprLPj4xYw2soJ5UDWoZBufgcIhXyyhVePLG4CLtHmFIjh7GSBI-aSpKy1J1kogywYwZInqSoYvh5hn0KosgreqasZPdP9X96qh9eXj_2bXpEn9HP9ODk-rNmFSh-acRy6fjd0_-V-AKuJYw8</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>ESTEY, Elihu H ; RAZA, Azra ; GREENBERG, Peter L ; CURTIN, Peter T ; KLIMEK, Virginia M ; SHAMMO, Jamile M ; THOMAS, Deborah ; KNIGHT, Robert D ; SCHMIDT, Michele ; WRIDE, Kenton ; ZELDIS, Jerome B ; LIST, Alan F ; REEVES, James A ; FELDMAN, Eric J ; DEWALD, Gordon W ; BENNETT, John M ; JOACHIM DEEG, H ; DREISBACH, Luke ; SCHIFFER, Charles A ; STONE, Richard M</creator><creatorcontrib>ESTEY, Elihu H ; RAZA, Azra ; GREENBERG, Peter L ; CURTIN, Peter T ; KLIMEK, Virginia M ; SHAMMO, Jamile M ; THOMAS, Deborah ; KNIGHT, Robert D ; SCHMIDT, Michele ; WRIDE, Kenton ; ZELDIS, Jerome B ; LIST, Alan F ; REEVES, James A ; FELDMAN, Eric J ; DEWALD, Gordon W ; BENNETT, John M ; JOACHIM DEEG, H ; DREISBACH, Luke ; SCHIFFER, Charles A ; STONE, Richard M</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><language>eng</language><publisher>Washington, DC: The Americain Society of Hematology</publisher><subject>Biological and medical sciences ; Hematologic and hematopoietic diseases ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences</subject><ispartof>Blood, 2008, Vol.111 (1)</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4010</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19953465$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>ESTEY, Elihu H</creatorcontrib><creatorcontrib>RAZA, Azra</creatorcontrib><creatorcontrib>GREENBERG, Peter L</creatorcontrib><creatorcontrib>CURTIN, Peter T</creatorcontrib><creatorcontrib>KLIMEK, Virginia M</creatorcontrib><creatorcontrib>SHAMMO, Jamile M</creatorcontrib><creatorcontrib>THOMAS, Deborah</creatorcontrib><creatorcontrib>KNIGHT, Robert D</creatorcontrib><creatorcontrib>SCHMIDT, Michele</creatorcontrib><creatorcontrib>WRIDE, Kenton</creatorcontrib><creatorcontrib>ZELDIS, Jerome B</creatorcontrib><creatorcontrib>LIST, Alan F</creatorcontrib><creatorcontrib>REEVES, James A</creatorcontrib><creatorcontrib>FELDMAN, Eric J</creatorcontrib><creatorcontrib>DEWALD, Gordon W</creatorcontrib><creatorcontrib>BENNETT, John M</creatorcontrib><creatorcontrib>JOACHIM DEEG, H</creatorcontrib><creatorcontrib>DREISBACH, Luke</creatorcontrib><creatorcontrib>SCHIFFER, Charles A</creatorcontrib><creatorcontrib>STONE, Richard M</creatorcontrib><title>Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary</title><title>Blood</title><subject>Biological and medical sciences</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNjstKBDEQRYMoOD7-oTbuJpJ-jfZ6UFy6cD8UnWo6Th5tqoYhP-R3GsQPcHW53APnXqhNM7TP2pjWXKqNMWan-_GpuVY3zJ_GNH3XDhv1_b4gE7TAcrIF0gyeInpnU3CWwEWQjJHnE7sUtaWVoqUoW_DprLPj4xYw2soJ5UDWoZBufgcIhXyyhVePLG4CLtHmFIjh7GSBI-aSpKy1J1kogywYwZInqSoYvh5hn0KosgreqasZPdP9X96qh9eXj_2bXpEn9HP9ODk-rNmFSh-acRy6fjd0_-V-AKuJYw8</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>ESTEY, Elihu H</creator><creator>RAZA, Azra</creator><creator>GREENBERG, Peter L</creator><creator>CURTIN, Peter T</creator><creator>KLIMEK, Virginia M</creator><creator>SHAMMO, Jamile M</creator><creator>THOMAS, Deborah</creator><creator>KNIGHT, Robert D</creator><creator>SCHMIDT, Michele</creator><creator>WRIDE, Kenton</creator><creator>ZELDIS, Jerome B</creator><creator>LIST, Alan F</creator><creator>REEVES, James A</creator><creator>FELDMAN, Eric J</creator><creator>DEWALD, Gordon W</creator><creator>BENNETT, John M</creator><creator>JOACHIM DEEG, H</creator><creator>DREISBACH, Luke</creator><creator>SCHIFFER, Charles A</creator><creator>STONE, Richard M</creator><general>The Americain Society of Hematology</general><scope>IQODW</scope></search><sort><creationdate>2008</creationdate><title>Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary</title><author>ESTEY, Elihu H ; RAZA, Azra ; GREENBERG, Peter L ; CURTIN, Peter T ; KLIMEK, Virginia M ; SHAMMO, Jamile M ; THOMAS, Deborah ; KNIGHT, Robert D ; SCHMIDT, Michele ; WRIDE, Kenton ; ZELDIS, Jerome B ; LIST, Alan F ; REEVES, James A ; FELDMAN, Eric J ; DEWALD, Gordon W ; BENNETT, John M ; JOACHIM DEEG, H ; DREISBACH, Luke ; SCHIFFER, Charles A ; STONE, Richard M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pascalfrancis_primary_199534653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ESTEY, Elihu H</creatorcontrib><creatorcontrib>RAZA, Azra</creatorcontrib><creatorcontrib>GREENBERG, Peter L</creatorcontrib><creatorcontrib>CURTIN, Peter T</creatorcontrib><creatorcontrib>KLIMEK, Virginia M</creatorcontrib><creatorcontrib>SHAMMO, Jamile M</creatorcontrib><creatorcontrib>THOMAS, Deborah</creatorcontrib><creatorcontrib>KNIGHT, Robert D</creatorcontrib><creatorcontrib>SCHMIDT, Michele</creatorcontrib><creatorcontrib>WRIDE, Kenton</creatorcontrib><creatorcontrib>ZELDIS, Jerome B</creatorcontrib><creatorcontrib>LIST, Alan F</creatorcontrib><creatorcontrib>REEVES, James A</creatorcontrib><creatorcontrib>FELDMAN, Eric J</creatorcontrib><creatorcontrib>DEWALD, Gordon W</creatorcontrib><creatorcontrib>BENNETT, John M</creatorcontrib><creatorcontrib>JOACHIM DEEG, H</creatorcontrib><creatorcontrib>DREISBACH, Luke</creatorcontrib><creatorcontrib>SCHIFFER, Charles A</creatorcontrib><creatorcontrib>STONE, Richard M</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ESTEY, Elihu H</au><au>RAZA, Azra</au><au>GREENBERG, Peter L</au><au>CURTIN, Peter T</au><au>KLIMEK, Virginia M</au><au>SHAMMO, Jamile M</au><au>THOMAS, Deborah</au><au>KNIGHT, Robert D</au><au>SCHMIDT, Michele</au><au>WRIDE, Kenton</au><au>ZELDIS, Jerome B</au><au>LIST, Alan F</au><au>REEVES, James A</au><au>FELDMAN, Eric J</au><au>DEWALD, Gordon W</au><au>BENNETT, John M</au><au>JOACHIM DEEG, H</au><au>DREISBACH, Luke</au><au>SCHIFFER, Charles A</au><au>STONE, Richard M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary</atitle><jtitle>Blood</jtitle><date>2008</date><risdate>2008</risdate><volume>111</volume><issue>1</issue><issn>0006-4971</issn><eissn>1528-0020</eissn><cop>Washington, DC</cop><pub>The Americain Society of Hematology</pub></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2008, Vol.111 (1)
issn 0006-4971
1528-0020
language eng
recordid cdi_pascalfrancis_primary_19953465
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Biological and medical sciences
Hematologic and hematopoietic diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
title Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Commentary
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A37%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%202%20study%20of%20lenalidomide%20in%20transfusion-dependent,%20low-risk,%20and%20intermediate-1-risk%20myelodysplastic%20syndromes%20with%20karyotypes%20other%20than%20deletion%205q.%20Commentary&rft.jtitle=Blood&rft.au=ESTEY,%20Elihu%20H&rft.date=2008&rft.volume=111&rft.issue=1&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/&rft_dat=%3Cpascalfrancis%3E19953465%3C/pascalfrancis%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true